# US 2008/0305181 A1 · Compositions and Methods for Treatment of Vascular Grafts

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305181 A1
- Document ID: US20080305181A1
- Status: Published application
- Kind: A1
- Application number: 11/578,490
- Filed: 2005-04-18
- Published: 2008-12-11
- Earliest claimed: 2004-04-20
- Inventors: Christopher D. Kontos; Jianhua Huang
- Web page: https://patentgrep.com/patent/US20080305181A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- C12N 9/16: acting on ester bonds (3.1)
- C12N 15/86: Viral vectors
- C12N 2710/10043: viral genome or elements thereof as genetic vector
- C12N 2710/10071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention contemplates compositions and methods for the treatment of vascular grafts both ex vivo and in vivo. Ex vivo treatment comprises completely removing a vessel (i.e., vein or artery) from the body and treating with the compositions of the present invention. In vivo treatment comprises treating the vessel in vivo without removing the vessel completely from the body (albeit one or both ends of the vessel may be closed off in order to focus the treatment in the desired area and/or avoid systemic treatment). In one embodiment, at least a portion of the smooth muscle cells of a vessel (e.g., vein or artery) are transfected ex vivo or in vivo with a vector capable of expressing at least one phosphatase. In a preferred embodiment, smooth muscle cells are transfected with adenovirus vector comprising the gene encoding PTEN.

## Claims

### Claim 1

A method, comprising:
a) providing;
i) a patient comprising a saphenous vein and first and second arteries, said saphenous vein comprising smooth muscle cells;
ii) an adenoviral vector comprising a nucleic acid encoding a PTEN amino acid sequence, said amino acid sequence selected from the group consisting of SEQ ID NO:1 and derivatives of SEQ ID NO:1, said derivatives comprising amino acid sequences comprising substitutions, said substitutions selected from the group consisting of Ser 6 Glu, Thr 6 Glu, Asp 6 Asn and Cys 6 Ser;
b) removing at least a portion of said saphenous vein from said patient to create a removed vein portion, wherein said removed vein portion comprises a first end and a second end; and
c) contacting said removed vein portion ex vivo with said vector under conditions such that said PTEN sequence is introduced into a least a portion of said smooth muscle cells to create a treated vein portion.

### Claim 2 (depends on 1)

The method of claim 1, wherein said amino acid sequence is proteasome resistant.

### Claim 3 (depends on 1)

The method of claim 1, wherein said patient has cardiovascular disease.

### Claim 4 (depends on 3)

The method of claim 3, wherein said cardiovascular disease comprises coronary artery disease.

### Claim 5 (depends on 1)

The method of claim 1, further comprising (d) introducing said treated vein portion into said patient.

### Claim 6 (depends on 5)

The method of claim 5, wherein said introducing comprises attaching said first end of said treated vein portion to said first artery under conditions such that a distal anastomosis is created.

### Claim 7 (depends on 5)

The method of claim 5, wherein said introducing further comprises attaching said second end of said treated vein portion to said second artery under condition such that a proximal anastomosis is created.

### Claim 8 (depends on 5)

The method of claim 5, wherein said first artery comprises a coronary artery.

### Claim 9 (depends on 6)

The method of claim 6, wherein said second artery comprises the aorta.

### Claim 10

A method, comprising:
a) providing;
i) a patient comprising a saphenous vein, a peripheral artery and a peripheral vein, said peripheral vein comprising smooth muscle cells;
ii) an adenoviral vector comprising a nucleic acid encoding a PTEN amino acid sequence, said amino acid sequence selected from the group consisting of SEQ ID NO:1 and derivatives of SEQ ID NO:1, said derivatives comprising amino acid sequences comprising substitutions, said substitutions selected from the group consisting of Ser 6 Glu, Thr 6 Glu, Asp 6 Asn and Cys 6 Ser;
b) removing at least a portion of said saphenous vein from said patient to create a removed vein portion, wherein said removed vein portion comprises a first end and a second end; and
c) contacting said removed vein portion ex vivo with said vector under conditions such that said PTEN sequence is introduced into a least a portion of said smooth muscle cells to create a treated vein portion.

### Claim 11 (depends on 10)

The method of claim 10, wherein said patient requires hemodialysis.

### Claim 12 (depends on 10)

The method of claim 10, wherein said hemodialysis comprises long-term maintenance.

### Claim 13 (depends on 9)

The method of claim 9, further comprising (d) introducing said treated vein portion into said patient to create an arterio-venous graft.

### Claim 14 (depends on 13)

The method of claim 13, wherein said introducing comprises attaching said first end of said treated saphenous vein portion to said peripheral artery under conditions such that a first anastomosis is created.

### Claim 15 (depends on 13)

The method of claim 13, wherein said introducing further comprises attaching said second end of said treated vein portion to said peripheral vein under conditions such that a second anastomosis is created.

### Claim 16 (depends on 13)

The method of claim 13, wherein said arterio-venous graft is selected from the group consisting of a wrist radiocephalic graft, a forearm radiocephalic graft and an antecubital brachiocephalic graft.

### Claim 17

A method, comprising:
a) providing;
i) a patient comprising a peripheral artery and a peripheral vein, said peripheral vein comprising smooth muscle cells;
ii) an adenoviral vector comprising a nucleic acid encoding a PTEN amino acid sequence, said amino acid sequence selected from the group consisting of SEQ ID NO:1 and derivatives of SEQ ID NO:1, said derivatives comprising amino acid sequences comprising substitutions, said substitutions selected from the group consisting of Ser 6 Glu, Thr 6 Glu, Asp 6 Asn and Cys 6 Ser;
b) connecting said peripheral artery and said peripheral vein such that an arterio-venous fistula is created:
c) contacting said arterio-venous fistula in vivo with said vector under conditions such that said PTEN sequence is introduced into a least a portion of said smooth muscle cells to create a treated arterio-venous fistula.

### Claim 18 (depends on 16)

The method of claim 16, wherein said patient has a renal disease.

### Claim 19 (depends on 17)

The method of claim 17, wherein said patient requires hemodialysis.

### Claim 20 (depends on 19)

The method of claim 19, wherein said hemodialysis comprises long-term maintenance.

### Claim 21 (depends on 17)

The method of claim 17, further comprising prior to step (c) ligating said arterio-venous fistula.

### Claim 22 (depends on 17)

The method of claim 17, wherein said arterio-venous fistula is selected from the group consisting of a wrist radiocephalic fistula, a forearm radiocephalic fistula and an antecubitat brachiocephalic fistula.

### Claim 23

A composition comprising an isolated tissue portion, said tissue portion being transfected by exposure to an adenovirus.

### Claim 24 (depends on 23)

The composition of claim 23, wherein said adenovirus encodes at least a portion of a PTEN gene.

### Claim 25 (depends on 23)

The composition of claim 23, wherein said tissue portion comprises a vascular tissue.
